High affinity interaction of mibefradil with voltage‐gated calcium and sodium channels
Mibefradil is a novel Ca2+ antagonist which blocks both high‐voltage activated and low voltage‐activated Ca2+ channels. Although L‐type Ca2+ channel block was demonstrated in functional experiments its molecular interaction with the channel has not yet been studied. We therefore investigated the bin...
Gespeichert in:
| Veröffentlicht in: | British journal of pharmacology 2000-06, Vol.130 (3), p.669-677 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 677 |
|---|---|
| container_issue | 3 |
| container_start_page | 669 |
| container_title | British journal of pharmacology |
| container_volume | 130 |
| creator | Eller, Philipp Berjukov, Stanislav Wanner, Siegmund Huber, Irene Hering, Steffen Knaus, Hans‐Günther Toth, Geza Kimball, S David Striessnig, Jörg |
| description | Mibefradil is a novel Ca2+ antagonist which blocks both high‐voltage activated and low voltage‐activated Ca2+ channels. Although L‐type Ca2+ channel block was demonstrated in functional experiments its molecular interaction with the channel has not yet been studied. We therefore investigated the binding of [3H]‐mibefradil and a series of mibefradil analogues to L‐type Ca2+ channels in different tissues.
[3H]‐Mibefradil labelled a single class of high affinity sites on skeletal muscle L‐type Ca2+ channels (KD of 2.5±0.4 nM, Bmax=56.4±2.3 pmol mg−1 of protein).
Mibefradil (and a series of analogues) partially inhibited (+)‐[3H]‐isradipine binding to skeletal muscle membranes but stimulated binding to brain L‐type Ca2+ channels and α1C‐subunits expressed in tsA201 cells indicating a tissue‐specific, non‐competitive interaction between the dihydropyridine and mibefradil binding domain.
[3H]‐Mibefradil also labelled a heterogenous population of high affinity sites in rabbit brain which was inhibited by a series of nonspecific Ca2+ and Na+‐channel blockers.
Mibefradil and its analogue RO40‐6040 had high affinity for neuronal voltage‐gated Na+‐channels as confirmed in binding (apparent Ki values of 17 and 1.0 nM, respectively) and functional experiments (40% use‐dependent inhibition of Na+‐channel current by 1 μM mibefradil in GH3 cells).
Our data demonstrate that mibefradil binds to voltage‐gated L‐type Ca2+ channels with very high affinity and is also a potent blocker of voltage‐gated neuronal Na+‐channels. More lipophilic mibefradil analogues may possess neuroprotective properties like other nonselective Ca2+‐/Na+‐channel blockers.
British Journal of Pharmacology (2000) 130, 669–677; doi:10.1038/sj.bjp.0703352 |
| doi_str_mv | 10.1038/sj.bjp.0703352 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1572110</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17674700</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5176-e830dffd6a260be2a4bbf0bafc7e46f6281e4dfed2ba63860997b2bd1764ba5f3</originalsourceid><addsrcrecordid>eNqFkc1uEzEUhS1ERUNgyxKNEGKXYI9nbGeDBBWQSpVgARI76_ov8chjh_FMq-x4BJ6RJ8FRoraw6cqW7nePj89B6AXBS4KpeJu7pep2S8wxpW39CM1Iw9mipYI8RjOMMV8QIsQ5eppzh3EZ8vYJOidY1ISv-Az9WPvNtgLnfPTjvvJxtAPo0adYJVf1Xlk3gPGhuvHjtrpOYYSN_fPr9wZGayoNQfupryCaKidzuOotxGhDfobOHIRsn5_OOfr-6eO3i_Xi6svny4v3VwvdkuLUCoqNc4ZBzbCyNTRKOazAaW4b5lgtiG2Ms6ZWwKhgeLXiqlam7DYKWkfn6N1Rdzep3hpt4zhAkLvB9zDsZQIv_51Ev5WbdC1Jy2tSMpyjNyeBIf2cbB5l77O2IUC0acqSE9Iy2vIHwWKJNxwfFF_9B3ZpGmJJQZbUieCCsAItj5AeUs6DdbeWCZaHamXuZKlWnqotCy_vf_QefuyyAK9PAORSTOktap_vOLpiTLQFo0fsxge7f-BV-eHrmjQNo38BmV_AKw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217187816</pqid></control><display><type>article</type><title>High affinity interaction of mibefradil with voltage‐gated calcium and sodium channels</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Eller, Philipp ; Berjukov, Stanislav ; Wanner, Siegmund ; Huber, Irene ; Hering, Steffen ; Knaus, Hans‐Günther ; Toth, Geza ; Kimball, S David ; Striessnig, Jörg</creator><creatorcontrib>Eller, Philipp ; Berjukov, Stanislav ; Wanner, Siegmund ; Huber, Irene ; Hering, Steffen ; Knaus, Hans‐Günther ; Toth, Geza ; Kimball, S David ; Striessnig, Jörg</creatorcontrib><description>Mibefradil is a novel Ca2+ antagonist which blocks both high‐voltage activated and low voltage‐activated Ca2+ channels. Although L‐type Ca2+ channel block was demonstrated in functional experiments its molecular interaction with the channel has not yet been studied. We therefore investigated the binding of [3H]‐mibefradil and a series of mibefradil analogues to L‐type Ca2+ channels in different tissues.
[3H]‐Mibefradil labelled a single class of high affinity sites on skeletal muscle L‐type Ca2+ channels (KD of 2.5±0.4 nM, Bmax=56.4±2.3 pmol mg−1 of protein).
Mibefradil (and a series of analogues) partially inhibited (+)‐[3H]‐isradipine binding to skeletal muscle membranes but stimulated binding to brain L‐type Ca2+ channels and α1C‐subunits expressed in tsA201 cells indicating a tissue‐specific, non‐competitive interaction between the dihydropyridine and mibefradil binding domain.
[3H]‐Mibefradil also labelled a heterogenous population of high affinity sites in rabbit brain which was inhibited by a series of nonspecific Ca2+ and Na+‐channel blockers.
Mibefradil and its analogue RO40‐6040 had high affinity for neuronal voltage‐gated Na+‐channels as confirmed in binding (apparent Ki values of 17 and 1.0 nM, respectively) and functional experiments (40% use‐dependent inhibition of Na+‐channel current by 1 μM mibefradil in GH3 cells).
Our data demonstrate that mibefradil binds to voltage‐gated L‐type Ca2+ channels with very high affinity and is also a potent blocker of voltage‐gated neuronal Na+‐channels. More lipophilic mibefradil analogues may possess neuroprotective properties like other nonselective Ca2+‐/Na+‐channel blockers.
British Journal of Pharmacology (2000) 130, 669–677; doi:10.1038/sj.bjp.0703352</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1038/sj.bjp.0703352</identifier><identifier>PMID: 10821797</identifier><identifier>CODEN: BJPCBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Biological and medical sciences ; Ca2+ channel blockers ; Calcium Channel Blockers - pharmacology ; Calcium Channels, L-Type - drug effects ; Cardiovascular system ; Electric Stimulation ; Electrophysiology ; Guinea Pigs ; In Vitro Techniques ; Ion Channel Gating - drug effects ; Medical sciences ; mibefradil ; Mibefradil - pharmacology ; Miscellaneous ; Muscle, Skeletal - drug effects ; Muscle, Skeletal - metabolism ; Patch-Clamp Techniques ; Pharmacology. Drug treatments ; Rabbits ; Radioligand Assay ; Sodium Channel Blockers</subject><ispartof>British journal of pharmacology, 2000-06, Vol.130 (3), p.669-677</ispartof><rights>2000 Nature Publishing Group</rights><rights>2000 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jun 2000</rights><rights>Copyright 2000, Nature Publishing Group 2000 Nature Publishing Group</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5176-e830dffd6a260be2a4bbf0bafc7e46f6281e4dfed2ba63860997b2bd1764ba5f3</citedby><cites>FETCH-LOGICAL-c5176-e830dffd6a260be2a4bbf0bafc7e46f6281e4dfed2ba63860997b2bd1764ba5f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572110/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572110/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,1427,27903,27904,45553,45554,46387,46811,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1396685$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10821797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eller, Philipp</creatorcontrib><creatorcontrib>Berjukov, Stanislav</creatorcontrib><creatorcontrib>Wanner, Siegmund</creatorcontrib><creatorcontrib>Huber, Irene</creatorcontrib><creatorcontrib>Hering, Steffen</creatorcontrib><creatorcontrib>Knaus, Hans‐Günther</creatorcontrib><creatorcontrib>Toth, Geza</creatorcontrib><creatorcontrib>Kimball, S David</creatorcontrib><creatorcontrib>Striessnig, Jörg</creatorcontrib><title>High affinity interaction of mibefradil with voltage‐gated calcium and sodium channels</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>Mibefradil is a novel Ca2+ antagonist which blocks both high‐voltage activated and low voltage‐activated Ca2+ channels. Although L‐type Ca2+ channel block was demonstrated in functional experiments its molecular interaction with the channel has not yet been studied. We therefore investigated the binding of [3H]‐mibefradil and a series of mibefradil analogues to L‐type Ca2+ channels in different tissues.
[3H]‐Mibefradil labelled a single class of high affinity sites on skeletal muscle L‐type Ca2+ channels (KD of 2.5±0.4 nM, Bmax=56.4±2.3 pmol mg−1 of protein).
Mibefradil (and a series of analogues) partially inhibited (+)‐[3H]‐isradipine binding to skeletal muscle membranes but stimulated binding to brain L‐type Ca2+ channels and α1C‐subunits expressed in tsA201 cells indicating a tissue‐specific, non‐competitive interaction between the dihydropyridine and mibefradil binding domain.
[3H]‐Mibefradil also labelled a heterogenous population of high affinity sites in rabbit brain which was inhibited by a series of nonspecific Ca2+ and Na+‐channel blockers.
Mibefradil and its analogue RO40‐6040 had high affinity for neuronal voltage‐gated Na+‐channels as confirmed in binding (apparent Ki values of 17 and 1.0 nM, respectively) and functional experiments (40% use‐dependent inhibition of Na+‐channel current by 1 μM mibefradil in GH3 cells).
Our data demonstrate that mibefradil binds to voltage‐gated L‐type Ca2+ channels with very high affinity and is also a potent blocker of voltage‐gated neuronal Na+‐channels. More lipophilic mibefradil analogues may possess neuroprotective properties like other nonselective Ca2+‐/Na+‐channel blockers.
British Journal of Pharmacology (2000) 130, 669–677; doi:10.1038/sj.bjp.0703352</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Ca2+ channel blockers</subject><subject>Calcium Channel Blockers - pharmacology</subject><subject>Calcium Channels, L-Type - drug effects</subject><subject>Cardiovascular system</subject><subject>Electric Stimulation</subject><subject>Electrophysiology</subject><subject>Guinea Pigs</subject><subject>In Vitro Techniques</subject><subject>Ion Channel Gating - drug effects</subject><subject>Medical sciences</subject><subject>mibefradil</subject><subject>Mibefradil - pharmacology</subject><subject>Miscellaneous</subject><subject>Muscle, Skeletal - drug effects</subject><subject>Muscle, Skeletal - metabolism</subject><subject>Patch-Clamp Techniques</subject><subject>Pharmacology. Drug treatments</subject><subject>Rabbits</subject><subject>Radioligand Assay</subject><subject>Sodium Channel Blockers</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkc1uEzEUhS1ERUNgyxKNEGKXYI9nbGeDBBWQSpVgARI76_ov8chjh_FMq-x4BJ6RJ8FRoraw6cqW7nePj89B6AXBS4KpeJu7pep2S8wxpW39CM1Iw9mipYI8RjOMMV8QIsQ5eppzh3EZ8vYJOidY1ISv-Az9WPvNtgLnfPTjvvJxtAPo0adYJVf1Xlk3gPGhuvHjtrpOYYSN_fPr9wZGayoNQfupryCaKidzuOotxGhDfobOHIRsn5_OOfr-6eO3i_Xi6svny4v3VwvdkuLUCoqNc4ZBzbCyNTRKOazAaW4b5lgtiG2Ms6ZWwKhgeLXiqlam7DYKWkfn6N1Rdzep3hpt4zhAkLvB9zDsZQIv_51Ev5WbdC1Jy2tSMpyjNyeBIf2cbB5l77O2IUC0acqSE9Iy2vIHwWKJNxwfFF_9B3ZpGmJJQZbUieCCsAItj5AeUs6DdbeWCZaHamXuZKlWnqotCy_vf_QefuyyAK9PAORSTOktap_vOLpiTLQFo0fsxge7f-BV-eHrmjQNo38BmV_AKw</recordid><startdate>200006</startdate><enddate>200006</enddate><creator>Eller, Philipp</creator><creator>Berjukov, Stanislav</creator><creator>Wanner, Siegmund</creator><creator>Huber, Irene</creator><creator>Hering, Steffen</creator><creator>Knaus, Hans‐Günther</creator><creator>Toth, Geza</creator><creator>Kimball, S David</creator><creator>Striessnig, Jörg</creator><general>Blackwell Publishing Ltd</general><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200006</creationdate><title>High affinity interaction of mibefradil with voltage‐gated calcium and sodium channels</title><author>Eller, Philipp ; Berjukov, Stanislav ; Wanner, Siegmund ; Huber, Irene ; Hering, Steffen ; Knaus, Hans‐Günther ; Toth, Geza ; Kimball, S David ; Striessnig, Jörg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5176-e830dffd6a260be2a4bbf0bafc7e46f6281e4dfed2ba63860997b2bd1764ba5f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Ca2+ channel blockers</topic><topic>Calcium Channel Blockers - pharmacology</topic><topic>Calcium Channels, L-Type - drug effects</topic><topic>Cardiovascular system</topic><topic>Electric Stimulation</topic><topic>Electrophysiology</topic><topic>Guinea Pigs</topic><topic>In Vitro Techniques</topic><topic>Ion Channel Gating - drug effects</topic><topic>Medical sciences</topic><topic>mibefradil</topic><topic>Mibefradil - pharmacology</topic><topic>Miscellaneous</topic><topic>Muscle, Skeletal - drug effects</topic><topic>Muscle, Skeletal - metabolism</topic><topic>Patch-Clamp Techniques</topic><topic>Pharmacology. Drug treatments</topic><topic>Rabbits</topic><topic>Radioligand Assay</topic><topic>Sodium Channel Blockers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eller, Philipp</creatorcontrib><creatorcontrib>Berjukov, Stanislav</creatorcontrib><creatorcontrib>Wanner, Siegmund</creatorcontrib><creatorcontrib>Huber, Irene</creatorcontrib><creatorcontrib>Hering, Steffen</creatorcontrib><creatorcontrib>Knaus, Hans‐Günther</creatorcontrib><creatorcontrib>Toth, Geza</creatorcontrib><creatorcontrib>Kimball, S David</creatorcontrib><creatorcontrib>Striessnig, Jörg</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eller, Philipp</au><au>Berjukov, Stanislav</au><au>Wanner, Siegmund</au><au>Huber, Irene</au><au>Hering, Steffen</au><au>Knaus, Hans‐Günther</au><au>Toth, Geza</au><au>Kimball, S David</au><au>Striessnig, Jörg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High affinity interaction of mibefradil with voltage‐gated calcium and sodium channels</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2000-06</date><risdate>2000</risdate><volume>130</volume><issue>3</issue><spage>669</spage><epage>677</epage><pages>669-677</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><coden>BJPCBM</coden><abstract>Mibefradil is a novel Ca2+ antagonist which blocks both high‐voltage activated and low voltage‐activated Ca2+ channels. Although L‐type Ca2+ channel block was demonstrated in functional experiments its molecular interaction with the channel has not yet been studied. We therefore investigated the binding of [3H]‐mibefradil and a series of mibefradil analogues to L‐type Ca2+ channels in different tissues.
[3H]‐Mibefradil labelled a single class of high affinity sites on skeletal muscle L‐type Ca2+ channels (KD of 2.5±0.4 nM, Bmax=56.4±2.3 pmol mg−1 of protein).
Mibefradil (and a series of analogues) partially inhibited (+)‐[3H]‐isradipine binding to skeletal muscle membranes but stimulated binding to brain L‐type Ca2+ channels and α1C‐subunits expressed in tsA201 cells indicating a tissue‐specific, non‐competitive interaction between the dihydropyridine and mibefradil binding domain.
[3H]‐Mibefradil also labelled a heterogenous population of high affinity sites in rabbit brain which was inhibited by a series of nonspecific Ca2+ and Na+‐channel blockers.
Mibefradil and its analogue RO40‐6040 had high affinity for neuronal voltage‐gated Na+‐channels as confirmed in binding (apparent Ki values of 17 and 1.0 nM, respectively) and functional experiments (40% use‐dependent inhibition of Na+‐channel current by 1 μM mibefradil in GH3 cells).
Our data demonstrate that mibefradil binds to voltage‐gated L‐type Ca2+ channels with very high affinity and is also a potent blocker of voltage‐gated neuronal Na+‐channels. More lipophilic mibefradil analogues may possess neuroprotective properties like other nonselective Ca2+‐/Na+‐channel blockers.
British Journal of Pharmacology (2000) 130, 669–677; doi:10.1038/sj.bjp.0703352</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>10821797</pmid><doi>10.1038/sj.bjp.0703352</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1188 |
| ispartof | British journal of pharmacology, 2000-06, Vol.130 (3), p.669-677 |
| issn | 0007-1188 1476-5381 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1572110 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; PubMed Central; Alma/SFX Local Collection |
| subjects | Animals Biological and medical sciences Ca2+ channel blockers Calcium Channel Blockers - pharmacology Calcium Channels, L-Type - drug effects Cardiovascular system Electric Stimulation Electrophysiology Guinea Pigs In Vitro Techniques Ion Channel Gating - drug effects Medical sciences mibefradil Mibefradil - pharmacology Miscellaneous Muscle, Skeletal - drug effects Muscle, Skeletal - metabolism Patch-Clamp Techniques Pharmacology. Drug treatments Rabbits Radioligand Assay Sodium Channel Blockers |
| title | High affinity interaction of mibefradil with voltage‐gated calcium and sodium channels |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T14%3A23%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20affinity%20interaction%20of%20mibefradil%20with%20voltage%E2%80%90gated%20calcium%20and%20sodium%20channels&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Eller,%20Philipp&rft.date=2000-06&rft.volume=130&rft.issue=3&rft.spage=669&rft.epage=677&rft.pages=669-677&rft.issn=0007-1188&rft.eissn=1476-5381&rft.coden=BJPCBM&rft_id=info:doi/10.1038/sj.bjp.0703352&rft_dat=%3Cproquest_pubme%3E17674700%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217187816&rft_id=info:pmid/10821797&rfr_iscdi=true |